SCHEMBL3528245

SCHEMBL3528245

COC(=O)C(C)(C)OCc1cc2cc(C(F)(F)F)ccc2n1S(=O)(=O)c1ccc2c(c1)CCN2C(C)=O

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.48
LMNA P02545 3/20 0.48
TSHR P16473 2/20 0.48
HTT P42858 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
USP2 O75604 1/20 0.48
GAA P10253 1/20 0.48
PKM P14618 1/20 0.48
TRIM24 O15164 1/20 0.47
PPARG P37231 7/20 0.44
PPARA Q07869 6/20 0.44
PPARD Q03181 5/20 0.44
MAPK1 P28482 1/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
POLB P06746 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3526704 0.92 NOTUM (0.50) NOTUMLMNATSHRHTTSMN1; SMN2
SCHEMBL3524003 0.89 TRIM24 (0.47) NOTUMLMNAHTTSMN1; SMN2PKM
SCHEMBL3528642 0.85 PPARG (0.52) NOTUMLMNATSHRHTTSMN1; SMN2
SCHEMBL3523138 0.84 PPARG (0.57) NOTUMLMNATSHRHTTSMN1; SMN2
SCHEMBL3523853 0.83 PPARG (0.46) GAAPKMPPARGPPARAPPARD
SCHEMBL3527552 0.82 PPARG (0.57) NOTUMLMNATSHRHTTSMN1; SMN2
SCHEMBL3528168 0.81 NOTUM (0.47) NOTUMLMNATRIM24PPARGPPARA
SCHEMBL3523095 0.81 PPARG (0.65) NOTUMLMNATSHRHTTSMN1; SMN2
SCHEMBL3520124 0.81 PPARG (0.46) HTTPPARGPPARAPPARD
SCHEMBL3521489 0.80 PPARG (0.50) PPARGPPARAPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436040-B2 Method of treating conditions involving PPAR-receptors with indole compounds LABORATOIRES FOURNIER S.A. (FR) 2013-05-07 US disclosed
US-20100286137-A1 Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds LABORATORIES FOURNIER S.A. (FR) 2010-11-11 US disclosed
US-7795297-B2 Indole compounds, method of preparing them and uses thereof LABORATORIES FOURNIER S.A. (FR) 2010-09-14 US disclosed
US-20080153816-A1 Indole Compounds, Method of Preparing Them and Uses Thereof LABORATOIRES FOURNIER S.A. (FR) 2008-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080153816-A1 Indole Compounds, Method of Preparing Them and Uses Thereof LIPG, GPR119, IAPP NOTUM 192/4885LMNA 849/4885TSHR 1967/4885
US-20100286137-A1 Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds GPR119, PPARA, PPARG NOTUM 743/4885LMNA 1980/4885TSHR 211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.